Publication & Citation Trends
Publications
0 total
Breast Cancer Tamoxifen Dose Escalation in Patients With Diminished CYP 2 D 6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Cited by 1
Semantic Scholar
Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity
Cited by 1
Semantic Scholar
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. OA
Cited by 49
Semantic Scholar
Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity
Cited by 5
Semantic Scholar
378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies
Cited by 7
Semantic Scholar
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. OA
Cited by 0
Semantic Scholar
Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races.
Cited by 1
Semantic Scholar
Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer OA
Cited by 42
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(12)
Colorectal Cancer Treatments and Studies
(12)
Cancer therapeutics and mechanisms
(10)
Lung Cancer Research Studies
(10)
Cancer Treatment and Pharmacology
(7)
Affiliations
University of North Carolina at Chapel Hill
Fox Chase Cancer Center
San Antonio Military Medical Center
Research Triangle Park Foundation
Cleveland Clinic